Maybe I’m wondering, “Will the COVID vaccines updated this fall work better than they do now?”
Because today people are working to prevent serious illness. The news should do the same. The ideal news we want is an opportunity to avoid infection and even a mild illness. Theoretically, a new vaccine adapted to the mutant spike protein in the Omicron variant should do so, rather than the spik protein in the original Wuhan virus.
The problem is that Omicron and its subvariants are irritated at re-infecting people. The fact that you have antibodies does not guarantee that you will not be re-infected. These antibodies are released faster than previous variants. And the Omicron lineage continues to mutate so quickly that new vaccines may become somewhat obsolete when they hit the market.
Thanks to the wonders of mRNA technology, vaccine production is faster than ever before. However, science cannot keep pace with viral evolution at this point.
So what now?
The new variants appear to be more immune-resistant than the original Omicron strain, and even recycled vaccines may become obsolete once they become available this fall.
A preliminary publication published last week found that antibodies to BA and BA.5, which appeared in South Africa, were much more stable than previous strains, as well as those that now dominate the United States. Infectious Infections…
“It takes six months for Omicron BA.1 vaccines to be properly tested, and then it takes longer to release them. That’s for sure, “said Cornell virologist John Moore.
“It’s very complicated. We’re far behind the virus, “he said. [Celine] Gunder added.
Gunder thinks they may have no choice but to update vaccines based on the original strain of Omicron, which swept the U.S. last winter, while derivatives such as BA.4 and BA.5 are more resistant to shot antibodies. Yes. On the other hand, it has never been clear that Omicron-specific vaccines provide more protection against infection than primary vaccines. Unless we have something new and qualitatively different, such as nasal sprays, which are designed to prevent infection by inhaling aerosol virus particles – we only need to be protected from serious illness.
This is certainly a nice reward, especially for older people. Older citizens who struggled with the Omicron, which was the “soft” option last winter, have done well. For those who have not been vaccinated, this has not been so mild:
Last year, when older citizens were not vaccinated for the first time and young people were not vaccinated, the age-related COVID mortality rate was temporarily lower than that of older adults. This year, with the general population gaining some degree of immunity, expectations have increased again with age. The super-infectious option, combined with enhanced intake and less backward precautions, resulted in a “tragic seizure of COVID and death in the elderly as“ pandemic thinking ”decreased. Is there anything that can be done to improve immunity other than an infinite number of enhancers?
Could be. The most interesting part I read today is an interview with a pharmaceutical analyst at Bloomberg News who thinks that the British have stumbled on a winning vaccine strategy. Remember that the first dose for many Britons was the Oxford / AstraZeneka vaccine, which is not available in the United States. This adenovirus vaccine differs from the mRNA technology used by Pfizer and Moderna, but is similar to the one used by Johnson and Johnson. Rarely, adenovirus vaccines cause blood clots, so recipients in the UK have been encouraged to switch to Pfizer for a second vaccination. They “mixed and matched” two different types of vaccines, in other words. And because they do, they may have more protection than us who are stuck with mRNA frames:
One month after the second shot, the level of neutralizing antibodies in the mixed vaccine group was 10 times higher than in two shots of the Pfizer (mRNA) axis, and one-third of the people in the latter group were not neutralized at all. This means that those who receive the mixed and compatible vaccine are not better protected from infection, and given the high levels of antibodies, this protection can be prolonged …
In fact, the study, which looked at the immune response to mRNA vaccines and the J&J and Novavax sections (also uses the adenovirus vector in Zhang et al., Produces a specific type of memory B-cell that is important for mucosal immunity) ) in two animal models. Mucous immunity is not shown after mRNA vaccines, which suggests greater protection against re-infection in those who received the J&J vaccine before or after the mRNA vaccine.
Nasal vaccines are aimed at providing mucous immunity. Here and in the UK, people who are initially exposed to the mRNA with the adenovirus vaccine may have better protection than others, perhaps because their immune systems have been trained to produce different arrays of antibodies. Interestingly, whether it works in reverse, those who receive the first series of mRNA vaccines will receive better protection if they switch to J&J amplifiers. Older citizens, of course, want to know.
Here, Pfizer board member Scott Gottlieb is optimistic about the effectiveness of the updated vaccines, which will arrive later this year.
“I hope this vaccine provides a high level of protection from these new options,” he says. @ScottGottliebMD. “I base this hypothesis on a review of some clinical data from South Africa.” pic.twitter.com/KjATJ1dDoJ
– Squawk Box (@SquawkCNBC) May 27, 2022